Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT00475878 · ClinicalTrials.gov registry record · Phase 3

SSRI and Buprenorphine

A Phase 3 study, sponsored by Butler Hospital.

Completed
Registry status
Phase 3
Development phase
147
Enrollment target

NCT00475878: Completed Phase 3 study, sponsored by Butler Hospital.

NCT00475878 is a Phase 3 study that has completed, run by Butler Hospital. The registered enrollment target is 147 participants, below the 772-participant average among 15,282 other Phase 3 trials with a reported enrollment target (81% lower). According to ClinicalTrials.gov, the official US trial registry.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT00475878, a Phase 3 study, has completed, sponsored by Butler Hospital.

COMPLETED
Registry status
Phase 3
Development phase
147 participants
Enrollment target

Study Summary

This study is designed to test whether treatment of depressive symptoms using escitalopram improves adherence to Buprenorphine and reduces symptoms of depression for individuals receiving Buprenorphine through their medical provider.

Primary Outcome

Drop-out is defined as 7 or more days of missed Buprenorphine doses

Interventions

  • DRUG placebo
  • DRUG escitalopram

Trial Details

FieldValue
Enrollment Target 147 participants
Start Date 2006-12
Est. Completion 2009-09
Phase Phase 3
Butler Hospital

103 total trials

What the finished NCT00475878 record still lists

NCT00475878 is an interventional study that assigns participants to a tested intervention. The registered 147 participants enrollment target is mid-sized for trials with a published cap, below the 772-participant average among 15,282 other Phase 3 trials with a reported enrollment target (81% lower).

The record links to 0 conditions, and to 2 interventions - of which placebo is the first listed.

NCT00475878 does not publish any study locations in the registry export this page uses.

Frequently Asked Questions

What is clinical trial NCT00475878 about?

NCT00475878 is a clinical study titled "SSRI and Buprenorphine". This study is designed to test whether treatment of depressive symptoms using escitalopram improves adherence to Buprenorphine and reduces symptoms of depression for individuals receiving Buprenorphine through their medical provider.

What is the current status of trial NCT00475878?

This trial is currently completed. It is a Phase 3 study. The enrollment target is 147 participants. The study started on 2006-12. Estimated completion is 2009-09.

What interventions are being tested in trial NCT00475878?

The interventions under investigation include: placebo (DRUG), escitalopram (DRUG).

Who is sponsoring clinical trial NCT00475878?

This trial is sponsored by Butler Hospital, which has 103 total clinical trials registered on ClinicalTrials.gov.

How this trial's enrollment target compares

Where NCT00475878's enrollment target sits among peer trials

147 1550th of 2000 higher than 450 of 2,000 other Phase 3 trials

participants (enrollment target), bucketed by value

Each bar is a band; taller bars hold more other Phase 3 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.

Source ClinicalTrials.gov registry export · 2026-08-08

Nationwide trials with similar profiles

Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.

Similar enrollment target

  • NCT04396613 · 147 participants · NA

    Wound Closure Techniques in Primary Spine Surgery

  • NCT04851119 · 147 participants · Phase 1

    Tegavivint for the Treatment of Recurrent or Refractory Solid Tumors, Including Lymphomas and Desmoid Tumors

  • NCT05523947 · 147 participants · Phase 1

    Clinical Trial of YH32367 in Patients With HER2 Positive Locally Advanced or Metastatic Solid Tumor

  • NCT06121843 · 147 participants · Phase 1

    A Study to Evaluate the Safety, Effectiveness and Tolerable Dose of Arlocabtagene Autoleucel (BMS-986393) in Novel Combinations in Participants With Relapsed and/or Refractory Multiple Myeloma

Similar registry start date

  • NCT05988463 · started 2027-01-01 · Phase 1

    Dose-Escalation Study of Artesunate Patients With IPF

  • NCT07219706 · started 2026-12-10 · NA

    Dietary Fiber and Time Restricted Eating

  • NCT02831335 · started 2026-12-01

    Technical Development of Multi-Parametric Renocerebral MRI

  • NCT05962346 · started 2026-12 · NA

    Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia

Source: ClinicalTrials.gov NCT00475878, the US trial registry maintained by the National Library of Medicine. NCT00475878 (mid enrollment · none site footprint · completed) retrieved and formatted by PlainTrial, see methodology.